Protein Summary
Plays a role in the process of neurogenesis. Required throughout embryonic neurogenesis to maintain neural progenitor cells, also called radial glial cells (RGCs), by allowing their daughter cells to choose progenitor over neuronal cell fate. Not required for the proliferation of neural progenitor cells before the onset of embryonic neurogenesis. Also required postnatally in the subventricular zone (SVZ) neurogenesis by regulating SVZ neuroblasts survival and ependymal wall integrity. Negative regulator of NF-kappa-B signaling pathway. The inhibition of NF-kappa-B activation is mediated at least in part, by preventing MAP3K7IP2 to interact with polyubiquitin chains of TRAF6 and RIPK1 and by stimulating the 'Lys-48'-linked polyubiquitination and degradation of TRAF6 in cortical neurons.
- ENST00000252891
- ENSP00000252891
- ENSG00000105245
- NBL
- CAG3A
- CTG3a
- NUMBR
- NUMB-R
- TNRC23
- NUMBLIKE
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
ligand (protein) perturbation | 0.83 | ||
histone modification site profile | 0.78 | ||
transcription factor | 0.7 | ||
cell type or tissue | 0.62 | ||
kinase perturbation | 0.6 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 83.86 (req: < 5)
Gene RIFs: 13 (req: <= 3)
Antibodies: 232 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 83.86 (req: >= 5)
Gene RIFs: 13 (req: > 3)
Antibodies: 232 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 8
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0